Form 4: Rapid Micro Biosystems CEO Reports Routine Stock Transactions Following RSU Vesting

Rapid Micro Biosystems' President and CEO, Robert G. Spignesi, Jr., reported the acquisition of shares from performance-based restricted stock units and subsequent sales to cover tax obligations.

Summary

• Robert G. Spignesi, Jr., President and CEO of Rapid Micro Biosystems, Inc. (RPID), reported a series of transactions involving Class A Common Stock between July 8 and July 10, 2025.
• He acquired a total of 75,433 shares (25,144 on July 8, 25,144 on July 9, and 25,145 on July 10) at a price of $0 per share. These acquisitions resulted from the satisfaction of performance criteria for previously granted restricted stock units (RSUs).
• Concurrently, Mr. Spignesi sold a total of 33,688 shares (10,824 on July 8, 11,247 on July 9, and 11,617 on July 10) to cover tax withholding obligations associated with the RSU vesting.
• The shares were sold at prices of $3.5127 on July 8, $3.5103 on July 9, and $3.398 on July 10.
• Following these transactions, Mr. Spignesi's direct beneficial ownership of Class A Common Stock stands at 944,015 shares.
• The reported beneficial ownership includes 29,904 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 14, 2025.

Sentiment

Score: 7

Explanation: The transactions reflect the vesting of performance-based equity awards, indicating the achievement of pre-defined criteria, followed by routine sales to cover tax obligations, which is a common practice and not indicative of a negative outlook. The net effect is an increase in beneficial ownership from the RSU vesting, even with the tax-related sales.

Positives

• The acquisition of 75,433 shares through the vesting of performance-based restricted stock units indicates the achievement of pre-defined performance criteria by the CEO.
• The vesting of RSUs at a $0 price reflects the conversion of equity awards into common stock, a form of compensation.

Negatives

• The sale of 33,688 shares, although for tax withholding purposes, results in a reduction of the CEO's direct beneficial ownership in the company.

Future Outlook

This Form 4 filing details past insider transactions and does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• Shares were acquired upon satisfaction of performance criteria underlying previously granted performance restricted stock units.
• The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance restricted stock units.

Industry Context

This filing is a routine disclosure of insider stock transactions, specifically related to executive compensation. It does not provide information directly related to broader industry trends or competitive landscape, but rather reflects an individual's equity movements within the company.

Related Party Transactions

• The acquisition of shares through RSU vesting represents a compensation transaction between the company and its CEO, a related party.
• The inclusion of shares acquired under the Employee Stock Purchase Plan (ESPP) also represents a transaction between the company and an employee, a related party.

Stakeholder Impact

• Shareholders: The vesting of RSUs and subsequent sales for tax purposes are routine events that slightly increase the public float of shares but are generally not considered significant drivers of share price.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates the company offers a benefit program that allows employees to acquire company stock.

Key Dates

Recommendation

Keywords

Rapid Micro Biosystems, RPID, Form 4, Insider Transaction, Stock Transaction, Restricted Stock Units, RSU Vesting, CEO, Director, Robert G. Spignesi Jr., Stock Sale, Stock Acquisition, Tax Withholding, Employee Stock Purchase Plan